In the case of cardiovascular disease, CRISPR gene editing can greatly reduce serum levels of PCSK9 and total cholesterol by targeting the PCSK9 gene in hepatocytes in vivo (Ding et al., 2014; Wang et al., 2016; Rossidis et al., 2018; Wang et al., 2018). The gene discussed is PCSK9; the disease is cardiovascular disorder.